AD Amyloid-Resilient Phenotype Study

📖 Wiki Page

experiment554 wordssynced 2026-04-02

Overview

flowchart TD experiments_ad_amyloid_resilie["AD Amyloid-Resilient Phenotype Study Why Some a"] experiments_ad_amyloid_resilie["Amyloid-Resilient"] experiments_ad_amyloid_resilie -->|"related to"| experiments_ad_amyloid_resilie style experiments_ad_amyloid_resilie fill:#81c784,stroke:#333,color:#000 experiments_ad_amyloid_resilie["Study"] experiments_ad_amyloid_resilie -->|"related to"| experiments_ad_amyloid_resilie style experiments_ad_amyloid_resilie fill:#81c784,stroke:#333,color:#000 experiments_ad_amyloid_resilie["experiment"] experiments_ad_amyloid_resilie -->|"related to"| experiments_ad_amyloid_resilie style experiments_ad_amyloid_resilie fill:#81c784,stroke:#333,color:#000 experiments_ad_amyloid_resilie["addresses"] experiments_ad_amyloid_resilie -->|"related to"| experiments_ad_amyloid_resilie style experiments_ad_amyloid_resilie fill:#81c784,stroke:#333,color:#000 style experiments_ad_amyloid_resilie fill:#4fc3f7,stroke:#333,color:#000

This experiment addresses the critical AD knowledge gap: "Why do some amyloid-positive people never get dementia?" (ranked #3 in AD Knowledge Gaps with 31 points). Understanding resilience mechanisms could reveal protective pathways applicable to all patients.

Key Question

What molecular, cellular, and network-level factors allow ~20-30% of amyloid-positive individuals to maintain normal cognitive function despite equivalent amyloid burden to AD patients?

Study Design

...

AD Amyloid-Resilient Phenotype Study

Overview

Mermaid diagram (expand to render)

Key Question

What molecular, cellular, and network-level factors allow ~20-30% of amyloid-positive individuals to maintain normal cognitive function despite equivalent amyloid burden to AD patients?

Study Design

Cohort Definition

Resilient cohort: amyloid-PET positive (Centiloids > 40), cognitively normal (MMSE ≥ 28, CDR = 0), age 65-85
AD cohort: amyloid-PET positive, mild cognitive impairment or early AD (CDR 0.5-1)
Control cohort: amyloid-PET negative, cognitively normal
Target n: 100 per group, matched for age, sex, education

Primary Outcomes

Identify differential gene expression signatures in peripheral immune cells

Map structural and functional brain network differences via MRI

Characterize CSF and plasma biomarker profiles

Quantify synaptic density via PET (SV2A ligand)

Study Timeline

Recruitment: 18 months
Baseline + 24-month follow-up: 36 months total
Interim analysis: 24 months
Final analysis: 48 months

Validation Protocol

Multi-omics Integration

Single-cell RNA-seq of peripheral blood mononuclear cells (PBMCs)

Proteomics panel: plasma p-tau217, p-tau181, NfL, GFAP, Aβ42/40

Metabolomics: broad metabolic profiling

epigenomic profiling: DNA methylation arrays

Neuroimaging Battery

Amyloid PET: Pittsburgh Compound B or flutemetamol

Tau PET: flortaucipir

Structural MRI: volumetric T1

fMRI: resting-state connectivity

FDG-PET: glucose metabolism

PET SV2A: synaptic density

Cognitive Assessment

Primary: CDR, MMSE, RBANS
Secondary: Trail-making A/B, digit symbol, verbal fluency
Ecological: smartphone-based cognitive monitoring

Expected Outcomes

Hypotheses to Test

Amyloid clearance efficiency: Resilient individuals show higher peripheral Aβ clearance rates

Tau buffering capacity: Resilient individuals have lower baseline tau burden OR efficient tau clearance

Synaptic resilience: Resilient individuals maintain higher synaptic density despite equivalent amyloid

Immune phenotype: Resilient individuals show anti-inflammatory microglial phenotype (TREM2-dependent)

Metabolic reserve: Resilient individuals have preserved cerebral glucose metabolism

Biomarker Panels for Validation

Resilience signature: combination of plasma markers that predicts cognitive preservation
Network resilience index: fMRI-based connectivity measure

Feasibility Assessment

| Factor | Assessment |
|--------|------------|
| Technical Feasibility | High — all assays and imaging are established |
| Recruitment Feasibility | Moderate — requires screening of ~500 individuals to identify 100 resilient |
| Cost Estimate | $8-12M total over 4 years |
| Timeline | 48 months to primary endpoints |
| Cross-Disease Value | High — resilience mechanisms may apply to all neurodegeneration |

Cost Breakdown

| Component | Cost (USD) |
|-----------|------------|
| Recruitment and screening | $2M |
| Multi-omics assays | $3M |
| Neuroimaging | $3M |
| Clinical coordination | $2M |
| Data analysis | $1M |
| Contingency (15%) | $1.7M |
| Total | $12.7M |

Risk Mitigation

Recruitment risk: Partner with A4 study, ARTUP, and similar prevention cohorts
Longitudinal attrition: Build 20% attrition buffer, use remote cognitive monitoring
Biomarker harmonization: Use standardized assays across sites (ADNI protocols)

[AD Knowledge Gaps Ranked](/gaps/ad-knowledge-gaps-ranked) — Gap #3
[Cognitive Reserve Mechanisms](/mechanisms/cognitive-reserve)
[ApoE and AD](/mechanisms/apoe4-alzheimers)
[Pre-symptomatic Tau Detection in MAPT Mutation Carriers](/experiments/pre-symptomatic-tau-detection-mapt)

References

[Petersen et al., SuperAging: cognitively supernormal elderly (2024)](https://pubmed.ncbi.nlm.nih.gov/)

[Resilience and Alzheimer's disease (2023)](https://doi.org/10.1038/s41583-023-00744-5)

[Amyloid and cognitive resilience (2023)](https://pubmed.ncbi.nlm.nih.gov/)

📖 View canonical wiki page →

AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Individuals Never Develop Dementia

AD Amyloid-Resilient Phenotype Study

Overview

Key Question

Study Design

AD Amyloid-Resilient Phenotype Study

Overview

Key Question

Study Design

Cohort Definition

Primary Outcomes

Study Timeline

Validation Protocol

Multi-omics Integration

Neuroimaging Battery

Cognitive Assessment

Expected Outcomes

Hypotheses to Test

Biomarker Panels for Validation

Feasibility Assessment

Cost Breakdown

Risk Mitigation

Related Experiments

References